Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 2/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071298 | 0.82 | TK2 (0.49) | SLC6A2ABCG2ABCB1RNASE1SHBG | |
| SCHEMBL3078216 | 0.78 | SLC6A2 (0.39) | SLC6A2ABCG2ABCB1RNASE1TYMS | |
| SCHEMBL9745089 | 0.77 | ABCG2 (0.53) | SLC6A2ABCG2ABCB1RNASE1 | |
| SCHEMBL3078239 | 0.76 | ALDH1A1 (0.42) | RNASE1TYMSSMN1; SMN2TK1 | |
| SCHEMBL3072159 | 0.76 | SMN1; SMN2 (0.44) | TYMSLMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL11575184 | 0.75 | SLC6A2 (0.61) | SLC6A2ABCG2RNASE1TK1 | |
| SCHEMBL11575187 | 0.75 | SLC6A2 (0.61) | SLC6A2ABCG2RNASE1TK1 | |
| SCHEMBL1172397 | 0.74 | TYMS (0.54) | TYMSLMNASMN1; SMN2TK1 | |
| SCHEMBL3079656 | 0.73 | TOP2A (0.42) | RNASE1TYMSSMN1; SMN2TK1 | |
| SCHEMBL3066260 | 0.73 | SMN1; SMN2 (0.44) | TYMSLMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054406-B1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | SLC6A2 858/4885ABCG2 1186/4885ABCB1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.